This evidence suggests that antibodies targeting CLCF1 or its receptors and the JAK/STAT pathway inhibitor may be novel therapeutic targets for primary FSGS and recurrent FSGS. The gene discussed is SOAT1; the disease is focal segmental glomerulosclerosis.